H. Nøkleby

发表

Considerations for controlling invasive meningococcal disease in high income countries.

J. Bettinger, J. Holst, H. Nøkleby, 2012, Vaccine.

Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine

H. Nøkleby, 2007, Expert review of vaccines.

Influenza vaccination in 22 developed countries: an update to 1995.

A. Ahlbom, I. Donatelli, H. Rebelo de Andrade, 1997, Vaccine.

Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian Childhood Immunisation Programme.

P. Magnus, L. Trogstad, S. Håberg, 2016, Vaccine.

Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia.

P. Aavitsland, H. Peltola, H. Nøkleby, 1999, The Journal of infectious diseases.

Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.

J. Tappero, B. Plikaytis, G. Carlone, 1999, JAMA.

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.

B. Plikaytis, C. Broome, G. Carlone, 1998, The Journal of infectious diseases.

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.

E. Rosenqvist, I. Aaberge, E. Høiby, 2003, Vaccine.

Management and control of communicable diseases in schools and other child care settings: systematic review on the incubation period and period of infectiousness

J. Semenza, C. Quinten, P. Lopalco, 2018, BMC Infectious Diseases.

Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey.

E. Rosenqvist, G. Bjune, E. Høiby, 1991, NIPH annals.

Bacille Calmette–Guérin vaccination of healthcare personnel: changing epidemiology calls for new recommendations in Norway

H. Nøkleby, T. Arnesen, A. Brantsæter, 2019, European Respiratory Journal.

Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines

E. Rosenqvist, I. Aaberge, A. Aase, 2007, Clinical and Vaccine Immunology.

Immunogenicity and Safety of a Combination of Two Serogroup B 1

I. Aaberge, A. Aase, H. Nøkleby, 2007 .

Persisting Immune Responses Indicating Long-Term Protection after Booster Dose with Meningococcal Group B Outer Membrane Vesicle Vaccine

E. Rosenqvist, I. Aaberge, H. Nøkleby, 2006, Clinical and Vaccine Immunology.

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.

K. Rasanathan, K. Mulholland, D. Lennon, 2006, Vaccine.

Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome.

H. Gjessing, P. Magnus, H. Nyland, 2009, Vaccine.

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

P. Aavitsland, H. Nøkleby, P. Oster, 2007, Vaccine.

A ‘tailor made’ vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand

R. Rappuoli, K. Nord, D. Lennon, 2003 .

Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.

A. Halstensen, E. Rosenqvist, T. Michaelsen, 1998, Developments in biological standardization.

Susceptibility to cytomegalovirus, parvovirus B19 and age‐dependent differences in levels of rubella antibodies among pregnant women

K. Vainio, H. H. Samdal, S. Dudman, 2014, Journal of medical virology.

Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.

G. Bjune, E. Høiby, H. Nøkleby, 1991, NIPH annals.

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

A. Halstensen, E. Rosenqvist, J. Eng, 1991, The Lancet.

Contributions of the Norwegian Institute of Public Health to the development of vaccines against serogroup B meningococcal disease.

E. Rosenqvist, J. Holst, H. Nøkleby, 2007, Vaccine.

Combined Administration of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine and Conjugated Serogroup C Vaccine Indicated for Prevention of Meningococcal Disease Is Safe and Immunogenic

I. Aaberge, E. Høiby, E. Ypma, 2005, Clinical Diagnostic Laboratory Immunology.

No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine.

G. Bjune, H. Nøkleby, E. Wedege, 1999, The Journal of infectious diseases.

The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials.

H. Nøkleby, B. Feiring, 1991, NIPH annals.

Prevention of viral hepatitis in the Nordic countries and Germany

W. Gerlich, G. François, L. Rombo, 2005, Scandinavian journal of infectious diseases.

Vaccination and anaphylaxis

H. Nøkleby, 2006, Current allergy and asthma reports.

Risk of fetal death after pandemic influenza virus infection or vaccination.

A. Wilcox, S. Vollset, P. Nafstad, 2013, The New England journal of medicine.

Is there an association between SV40 contaminated polio vaccine and lymphoproliferative disorders? An age–period–cohort analysis on Norwegian data from 1953 to 1997

B. Møller, T. Grotmol, H. Nøkleby, 2006, International journal of cancer.

Risk groups and other target groups - preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010-11.

A. Nicoll, H. Nøkleby, 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine

E. Rosenqvist, G. Bjune, J. Kolberg, 1995, Infection and immunity.

Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.

M. Gold, S. Halperin, U. Heininger, 2004, Vaccine.

Protection against poliomyelitis in Europe.

K. Johansen, P. Kreidl, H. Nøkleby, 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Immunisation of healthcare workers in the Nordic countries: Variation in recommendations and practices and a lack of assessment.

A. Lindstrand, T. Gudnason, T. Dub, 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Monitoring of timely and delayed vaccinations: a nation-wide registry-based study of Norwegian children aged < 2 years

H. Nøkleby, M. Bergsaker, I. L. Haugen, 2015, BMC Pediatrics.

Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.

E. Rosenqvist, G. Bjune, E. Høiby, 1991, NIPH annals.

Applicability of evidence-based practice in public health: risk assessment on Q fever under an ongoing outbreak.

J. Giesecke, D. Coulombier, F. Forland, 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Risk of fetal death after pandemic influenza virus infection or vaccination.

A. Wilcox, S. Vollset, P. Nafstad, 2013, The New England journal of medicine.

Applicability of evidence-based practice in public health : risk assessment on Q fever under an ongoing outbreak 5

Healy, Goossens, Belgium, 2012 .

Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome.

H. Gjessing, P. Magnus, H. Nyland, 2009, Vaccine.